Longevity & Aging · Metabolic & Cardiometabolic
insulin resistance and metabolic dysfunction increases Alzheimers disease risk
In plain terms: Does insulin resistance raise your risk of Alzheimer's?
Part of: • Insulin & Metabolic Aging
Yes — insulin resistance and diabetes are robustly linked to higher dementia/Alzheimer's risk observationally and mechanistically, but interventional trials targeting brain insulin have so far failed, so causation and the type-3-diabetes label remain unproven.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Population patterns (Observational)
How the studies fall
What the evidence shows
Causal-review pass (2026-08-14) — `causal_basis: association-only`. The association is large, consistent and mechanistically attractive -- 13 observational appraisals, several high quality, across ARIC, Hisayama, Korean NHIS. And the causal tests have failed. The intranasal-insulin meta-analysis (s41436338) is `tested-null`, and the 2026 evoke RCT (s41865758, high quality) is `tested-null`.
The evidence (16)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Ge 2026 · J Gerontol A Biol Sci Med Sci | observational | supports | moderate | Prospective cohort found longitudinal increases in TyG index associated with higher incident dementia risk. |
| Sarnowski 2023 · Clin Epigenetics | mechanism | supports | moderate | Multi-tissue epigenetic analysis identified shared methylation signatures linking insulin resistance and Alzheimer's disease at the CPT1A locus. |
| Morris 2016 · Neurobiol Aging | observational | mixed | low | Cognitively impaired elderly showed greater insulin resistance than controls, but insulin infusion did not improve memory, complicating a direct causal claim. |
| Wei Y 2026 · Medicine (Baltimore) | observational | mixed | low | Cross-sectional NHANES analysis: higher cardiovascular health (Life's Essential 8) associated with better cognition; blood glucose was the second-largest contributing component (weight 0.19) after physical activity. |
| Gutierrez-Tordera 2025 · J Gerontol A Biol Sci Med Sci | observational | supports | moderate | Metabolic signature of insulin resistance was associated with progression from MCI to Alzheimer's dementia. |
| Rawlings 2014 · Ann Intern Med | observational | supports | high | ARIC cohort: midlife diabetes (and prediabetes) associated with substantially greater 20-year cognitive decline, supporting a metabolic-dysfunction to cognition link. |
| Hong 2021 · Alzheimers Res Ther | observational | supports | high | Large population-based study found higher TyG index associated with elevated incident dementia risk. |
| Jun JE 2026 · Diabetes Obes Metab | observational | supports | high | Korean nationwide cohort (n=1,322,651): dementia incidence and adjusted HRs vs non-diabetic were 1.29 (T2DM+oral agents), 2.14 (T2DM+insulin), and 2.35 (T1DM) for all-cause dementia, with similar trends for AD and vascular dementi |
| Kang S 2026 · Metabolomics | observational | supports | low | CARDIA study (n=606, middle-aged): fasting glucose was negatively associated with cognition, with several metabolites mediating the glucose-cognition pathway. |
| Matsuzaki 2010 · Neurology | observational | supports | high | Autopsy-based Hisayama cohort found higher HOMA-IR/fasting insulin associated with increased neuritic plaque (AD pathology) burden. |
| Sun 2023 · Am J Prev Med | observational | supports | moderate | Prospective cohort found higher TyG index (insulin-resistance surrogate) associated with increased incident Alzheimer's disease risk. |
| Cummings 2026 · Lancet | RCT | tested-null | high | EVOKE/EVOKE+ phase-3 RCTs: oral semaglutide (GLP-1RA) gave no clinical benefit in early Alzheimer's despite strong observational/preclinical signals — undercuts a simple metabolic-causation-of-established-AD model. |
| Tseng 2026 · Biomed J | observational | mixed | moderate | Epidemiologic review: diabetes raises dementia risk about 56%, but the effect is stronger for vascular dementia than for amyloid-driven Alzheimer's — nuancing the AD-equals-diabetes framing. |
| Rotonen S 2026 · Scand J Prim Health Care | observational | supports | moderate | Longitudinal cohort (ages 57-69): greater increases in HOMA-IR (OR 2.20, 95% CI 1.05-4.62) and fasting insulin (OR 3.49, 95% CI 1.48-8.23) increased risk of mild cognitive impairment. |
| Silva 2026 · Rev Neurol | meta-analysis | tested-null | moderate | Meta-analysis of intranasal-insulin RCTs for MCI/AD: evidence inconsistent, no reliable clinical benefit — the direct fix-brain-insulin test does not confirm causation. |
| Schwartz 2025 · Neuroprotection | observational | supports | low | Mechanistic review: brain hyperinsulinemia, hyperglycemia and insulin resistance are independent AD risk factors via impaired insulin signaling and BBB dysfunction. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.